How to Get Dayvigo (Lemborexant) in Arkansas

What Is Dayvigo and Why Would You Need It?

Dayvigo (lemborexant) is a dual orexin receptor antagonist (DORA) that the FDA approved in December 2019 for the treatment of insomnia in adults who have difficulty falling asleep or staying asleep. Unlike older sedative-hypnotics such as zolpidem, lemborexant works by blocking orexin neuropeptides that promote wakefulness rather than broadly suppressing the central nervous system. This mechanism produces sleep that more closely resembles natural architecture.

The SUNRISE-1 trial (N=1,006) demonstrated that lemborexant 5 mg and 10 mg significantly reduced latency to persistent sleep compared to placebo and the comparator zolpidem extended-release 6.25 mg. Patients on lemborexant 10 mg fell asleep an average of 10.5 minutes faster than those on placebo (P<0.001) and experienced fewer next-morning residual effects than those on zolpidem ER [1]. That cleaner side-effect profile matters for anyone driving Arkansas highways at dawn.

Insomnia affects roughly 30% of U.S. adults at some point, with 10% meeting criteria for chronic insomnia disorder according to the American Academy of Sleep Medicine [2]. Arkansas ranks among the top ten states for self-reported short sleep duration per the CDC's Behavioral Risk Factor Surveillance System, with approximately 39% of adults reporting fewer than seven hours of sleep per night [3]. Access to newer, evidence-based therapies like lemborexant is therefore a real clinical need in the state.

Step-by-Step: Getting a Dayvigo Prescription in Arkansas

The process is straightforward. You need a diagnosis, a licensed prescriber, and a pharmacy willing to fill a Schedule IV controlled substance. Here is how each step works in Arkansas.

Step 1: Clinical evaluation. A prescriber must document your insomnia history, rule out secondary causes (obstructive sleep apnea, restless legs syndrome, medication-induced wakefulness), and confirm that cognitive behavioral therapy for insomnia (CBT-I) has been considered. The American Academy of Sleep Medicine clinical practice guideline recommends CBT-I as first-line treatment, with pharmacotherapy reserved for patients who do not respond adequately or cannot access CBT-I [2].

Step 2: Prescription. Your prescriber writes a prescription for lemborexant 5 mg or 10 mg. The FDA label recommends starting at 5 mg, taken no more than once per night immediately before bedtime with at least 7 hours of intended sleep remaining [4]. Because Dayvigo is Schedule IV, Arkansas law permits electronic prescribing for this medication (unlike Schedule II drugs, which have additional requirements).

Step 3: Pharmacy fill. You can fill at any licensed retail or mail-order pharmacy in Arkansas. If your insurance requires prior authorization, your prescriber's office will submit the necessary documentation, which typically takes 2 to 5 business days.

Telehealth Prescribing of Dayvigo in Arkansas

Arkansas permits telehealth prescribing of Schedule IV controlled substances. This is good news for patients in rural parts of the state, where sleep specialists may be over 90 miles away.

Under the Arkansas Telemedicine Act (Ark. Code Ann. § 17-80-402), a prescriber licensed in Arkansas can evaluate a patient via synchronous audio-video visit and prescribe lemborexant if clinical criteria are met. The prescriber must establish a legitimate provider-patient relationship during the encounter. No in-person visit is required as a prerequisite for Schedule IV prescriptions in Arkansas, though some insurance plans may have their own policies.

Several national telehealth platforms serve Arkansas patients for insomnia management. When selecting a provider, confirm three things: (1) the clinician holds an active Arkansas medical license, (2) the platform can send electronic prescriptions to Arkansas pharmacies, and (3) the clinician is comfortable prescribing DORAs specifically, since some telehealth providers default to trazodone or hydroxyzine.

The typical telehealth visit for insomnia takes 15 to 25 minutes. Your prescriber will ask about sleep onset latency, wake-after-sleep-onset time, total sleep time, and daytime impairment. Keep a sleep diary for at least one week before your appointment. This data gives the prescriber the clinical picture needed to justify lemborexant over older alternatives.

Who Can Prescribe Dayvigo in Arkansas?

Multiple provider types hold prescriptive authority for Schedule IV medications in Arkansas. Each has specific scope-of-practice rules.

Physicians (MD and DO) have unrestricted authority to prescribe lemborexant. Board-certified sleep medicine physicians, psychiatrists, and primary care doctors are the most common prescribers.

Nurse Practitioners (APRN-CNP) can prescribe Schedule IV drugs in Arkansas under a collaborative practice agreement with a physician. Arkansas does not grant full practice authority to NPs. The collaborative agreement must be on file with the Arkansas State Board of Nursing, and the collaborating physician must be available for consultation [5].

Physician Assistants (PA) prescribe under physician supervision per the Arkansas State Medical Board. A PA's supervising physician must authorize Schedule IV prescribing within the delegation agreement. In practice, most family medicine and internal medicine PAs can prescribe Dayvigo once the supervising physician approves.

Psychologists and other non-prescribers cannot prescribe lemborexant in Arkansas. However, psychologists trained in behavioral sleep medicine can provide CBT-I and refer to a prescriber for adjunctive pharmacotherapy when needed.

Arkansas Medicaid and Insurance Coverage

Arkansas Medicaid covers Dayvigo, but requires prior authorization. That process involves specific documentation.

For Arkansas Medicaid (managed through the Provider-Led Arkansas Shared Savings Entity, or PASSE, plans for behavioral health), the prior authorization request typically requires: (1) documented diagnosis of insomnia disorder using ICD-10 code G47.00 or G47.01, (2) evidence that at least one first-line agent (such as a generic sedative-hypnotic or trazodone) was tried and failed or is contraindicated, and (3) a statement that CBT-I was considered.

Commercial insurers vary. Many Arkansas Blue Cross Blue Shield plans place Dayvigo on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) formularies. Without a copay card, the out-of-pocket cost on a Tier 3 plan can range from $50 to $150 per month. With the Eisai copay assistance program, eligible commercially insured patients may pay as little as $0 per 30-day supply, with a maximum annual benefit that resets each calendar year.

The SUNRISE-2 trial (N=949) provides data that can strengthen prior authorization appeals. In that 12-month study, lemborexant 5 mg and 10 mg maintained efficacy on both subjective sleep onset latency and subjective wake-after-sleep-onset through one year of nightly use, without evidence of dose escalation or rebound insomnia upon discontinuation [6]. Dr. Margaret Moline, then vice president of clinical research at Eisai, noted that "the sustained efficacy over 12 months with no evidence of abuse potential distinguishes lemborexant from earlier hypnotic classes." This durability data is particularly persuasive when an insurer questions the cost differential over generic zolpidem.

Pharmacy Access and 503A Compounding in Arkansas

Dayvigo is available at all major retail pharmacy chains operating in Arkansas, including Walmart, Walgreens, CVS, and Kroger pharmacy locations. Specialty pharmacies are not required because lemborexant is an oral tablet with standard storage conditions.

Arkansas also licenses 503A compounding pharmacies under the authority of the Arkansas State Board of Pharmacy. A 503A pharmacy may compound a patient-specific prescription for lemborexant if a licensed prescriber determines that a commercially available formulation is not suitable for a particular patient (for example, a patient who cannot swallow tablets and needs an oral suspension). The compounded product must be dispensed pursuant to an individual prescription and cannot be prepared in bulk for general distribution. Patients should verify that their chosen compounding pharmacy holds an active Arkansas Board of Pharmacy license and that the pharmacist has documented the clinical rationale for compounding rather than dispensing the commercially available tablet.

Mail-order pharmacies can ship Dayvigo to Arkansas addresses. Because lemborexant is Schedule IV, not Schedule II, there are fewer restrictions on mail-order dispensing. Most pharmacy benefit managers (PBMs) include mail-order as an option, often at a lower copay for a 90-day supply compared to three separate 30-day retail fills.

Labs and Monitoring Before Starting Dayvigo

No routine laboratory tests are required before starting lemborexant. This is a notable advantage over some other insomnia-adjacent therapies.

The FDA prescribing information does not mandate blood work prior to initiation [4]. Your prescriber may, however, order tests to rule out conditions that mimic or worsen insomnia. Common pre-treatment evaluations include:

• Thyroid panel (TSH): Hyperthyroidism can cause insomnia. A TSH level helps exclude this.
• Comprehensive metabolic panel: Liver function tests are relevant because lemborexant is metabolized by CYP3A4. Patients with severe hepatic impairment (Child-Pugh C) should not take Dayvigo, and those with moderate impairment (Child-Pugh B) require a maximum dose of 5 mg [4].
• Sleep study (polysomnography): If obstructive sleep apnea is suspected based on symptoms like loud snoring, witnessed apneas, or a high STOP-BANG score, a sleep study should be completed before initiating any hypnotic. Treating insomnia without addressing concurrent sleep apnea is clinically incomplete.

The AASM's 2017 guideline on pharmacologic treatment of chronic insomnia, authored by Sateia et al., states: "Clinicians should conduct a thorough evaluation, including assessment for comorbid medical and psychiatric conditions, before initiating pharmacotherapy for insomnia" [2]. This recommendation applies to all hypnotics, not specifically to lemborexant.

Cost-Saving Strategies for Arkansas Patients

Dayvigo's average retail price without insurance is approximately $380 to $420 for a 30-day supply. Several strategies can reduce this significantly.

Eisai copay card. Available at dayvigo.com for commercially insured patients. Patients with Medicare Part D, Medicaid, or other government insurance are not eligible. The card may cover the full copay up to a specified annual maximum.

Patient assistance programs. Eisai offers the Eisai Patient Assistance Program for uninsured or underinsured patients who meet income criteria (generally below 400% of the federal poverty level). Applications require documentation of household income and a prescriber's signature.

GoodRx and similar discount platforms. Cash prices at Arkansas pharmacies vary widely. Using a discount card can bring the price down to roughly $330 to $370 per month at select locations. Compare prices across pharmacies in your area, because the spread between the cheapest and most expensive pharmacy in a single city can exceed $80.

90-day mail order. If your insurance covers Dayvigo, a 90-day mail-order fill typically costs two copays instead of three, saving one copay cycle per quarter.

Step therapy appeals. If your insurer denies Dayvigo and requires step therapy through zolpidem or suvorexant first, your prescriber can file an exception. Clinical documentation of adverse effects from the required step-therapy agents, a history of substance use disorder that makes benzodiazepine receptor agonists risky, or SUNRISE trial data showing lemborexant's differentiated safety profile can support the appeal.

How Lemborexant Compares to Other Arkansas-Available Insomnia Drugs

Understanding where Dayvigo fits helps both patients and prescribers justify its use.

The DORA class now includes two FDA-approved agents: suvorexant (Belsomra, approved 2014) and lemborexant (Dayvigo, approved 2019). In a post-hoc analysis of the SUNRISE-1 data, lemborexant 10 mg showed a 16.5-minute reduction in latency to persistent sleep versus placebo, compared to 10.5 minutes for zolpidem ER 6.25 mg, with significantly fewer morning-after balance impairments [1]. The balance finding is clinically relevant. Falls are a leading cause of injury among older adults, and the American Geriatrics Society Beers Criteria list benzodiazepine receptor agonists (including zolpidem) as potentially inappropriate for adults 65 and older [7].

Dr. Andrew Krystal, professor of psychiatry and behavioral sciences at the University of California, San Francisco, has said about the DORA class: "Orexin receptor antagonists represent the first new mechanism for insomnia treatment in decades, and the data suggest a more favorable risk-benefit profile in older adults compared to GABAergic agents." This perspective is reflected in the growing prescriber preference for DORAs among geriatric patients, a population that makes up a disproportionately large share of insomnia cases in Arkansas's aging communities.

Suvorexant (Belsomra) is the closest comparator. No head-to-head trial has directly compared suvorexant to lemborexant. Suvorexant's maximum dose is 20 mg, with common prescribing at 10 mg. Both drugs carry the same class warnings (sleep paralysis, hypnagogic hallucinations, cataplexy-like symptoms), though post-marketing reports suggest these effects are infrequent with either agent.

Generic zolpidem remains the cheapest option at under $10 per month. Trazodone is prescribed off-label for insomnia at low doses (25 to 100 mg) and costs even less. For patients without contraindications to these agents and without insurance coverage for Dayvigo, these remain pragmatic starting points.

Timeline: From First Appointment to First Dose

Knowing what to expect removes uncertainty from the process.

• Day 1: Schedule a telehealth or in-person visit with a licensed Arkansas prescriber. Many telehealth platforms offer appointments within 24 to 48 hours.
• Day 2 to 3: Complete your visit. If the prescriber determines lemborexant is appropriate, the electronic prescription is sent to your pharmacy that same day.
• Day 3 to 5: Your pharmacy processes the prescription. If prior authorization is required, the pharmacy notifies the prescriber's office, which submits the PA request to your insurer. Standard PA turnaround under Arkansas Medicaid is 24 to 72 hours.
• Day 5 to 7: Pick up your prescription or receive it via mail order. Take your first dose immediately before bedtime with at least 7 hours of sleep opportunity ahead of you. Do not take it with or immediately after a high-fat meal, as this can delay onset by approximately 1.5 hours [4].

If prior authorization is denied, your prescriber can file an appeal. Most commercial insurers in Arkansas must respond to a standard appeal within 30 days, though expedited appeals for urgent clinical situations require a response within 72 hours per the Arkansas Insurance Department.